What is immunitoAI?
Founded in 2020 and headquartered in Bengaluru, India, immunitoAI is an in-silico Antibody Discovery company leveraging Artificial Intelligence to provide rapid and accurate solutions. The company's core competency lies in its AI-driven platform, designed to accelerate the antibody discovery process, a critical step in biopharmaceutical research and development. This focus positions immunitoAI at the intersection of biotechnology and advanced computing, aiming to streamline drug discovery pipelines.
How much funding has immunitoAI raised?
immunitoAI has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2021): $1M with participation from Pi Ventures and Entrepreneur First
Key Investors in immunitoAI
Pi Ventures
Pi Ventures is a venture capital firm based in Bangalore, India, focusing on investments in companies developing artificial intelligence, machine learning, and IoT technologies.
Entrepreneur First
Entrepreneur First is an organization that provides resources and support for entrepreneurs, often acting as a launchpad for new ventures.
What's next for immunitoAI?
The recent major strategic investment signals a pivotal growth phase for immunitoAI. This capital infusion is expected to fuel further development of its AI-powered discovery engine, expand its research capabilities, and potentially broaden its market reach within the global biopharmaceutical sector. The company's trajectory suggests a move towards scaling its operations and solidifying its position as a key player in AI-driven drug discovery, aiming to accelerate the delivery of novel therapeutics.
See full immunitoAI company page
